Sun Pharmaceutical Industries Ltd. said Oct. 23 that the company appointed Jeremy Allen as vice president, corporate affairs for North America. In this newly created position, he will lead Sun Pharma’s government affairs, public policy, advocacy and communications across the U.S. and Canada.
“With his expertise and strategic vision, Jeremy will serve an integral role in the continued growth of our business,” said Richard Ascroft, Sun Pharma CEO, North America. “Jeremy and his team will strengthen our engagement with stakeholders, shape policy environments, and ensure our voice reflects the values and priorities of the people who rely on our innovative medicines, generics and consumer health-care products.”
In this role, Allen will lead Sun Pharma’s external engagement, policy initiatives, patient advocacy, government relations and corporate communications across the United States and Canada.
“As Sun Pharma launches new innovative medicines that address unmet patient needs and generics that play a vital role in lowering costs for the health-care system, this role will be pivotal in continuing the company’s efforts to build trust, deepen existing relationships and ensure we’re meeting the needs of the patient communities we serve,” said Allen.
Allen has over 25 years of industry experience and an extensive background in developing and leading campaign-style policy initiatives. He joins Sun Pharma from Spark Therapeutics, where he led the U.S. government affairs and pricing and reimbursement functions.
Prior to his time with Spark, Allen led the federal lobbying team at AHIP (formerly known as America’s Health Insurance Plans) and held government affairs roles at Vertex Pharmaceuticals and Johnson & Johnson. Allen began his career in government, working both on Capitol Hill and at the Centers for Disease Control and Prevention.
Sun Pharma is a specialty generics company with a presence in innovative medicines, generics and consumer health care products.
